Related Experiment Video
Updated: Aug 9, 2026
05:46
A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Summary: systemic effects of inhaled nitric oxide
1Pediatric Respiratory Medicine, University of Virginia Children's Hospital, Charlottesville, VA 22908, USA. bmg3g@virginia.edu
Proceedings of the American Thoracic Society
|March 28, 2006
Summary
Inhaled nitric oxide (NO) has systemic effects beyond traditional pathways, impacting blood flow and leukocyte behavior. This therapy shows potential for treating conditions involving NO synthase inhibition and ischemia/reperfusion injury.
Area of Science:
- Biochemistry
- Physiology
- Pharmacology
Background:
- Traditional understanding of inhaled nitric oxide (NO) focuses on pulmonary guanylate cyclase activation and heme inactivation.
- Emerging evidence suggests NO has systemic effects not explained by these conventional mechanisms.
- Inhaled NO influences systemic vascular beds, particularly during ischemia/reperfusion and affects leukocyte dynamics.
Purpose of the Study:
- To review whole-animal studies on the systemic effects of inhaled NO.
- To explore the complex biochemistry and NO transfer biology of inhaled NO therapy.
- To highlight the therapeutic potential of inhaled NO beyond pulmonary applications.
Main Methods:
- Review of existing whole-animal studies on inhaled nitric oxide.
- Analysis of NO biochemistry, including reactions with circulating proteins.
- Examination of NO transport from the lungs to the systemic periphery.
Main Results:
- Inhaled NO demonstrates systemic effects, including modulation of blood flow in various vascular beds and influencing leukocyte adhesion and rolling.
- Inhaled NO therapy can counteract systemic effects caused by nitric oxide synthase inhibition.
- Systemic effects appear to involve NO reacting with proteins and being transported from the lungs.
Conclusions:
- The systemic actions of inhaled NO involve complex NO transfer biology, extending beyond pulmonary effects.
- Inhaled NO exhibits NO synthase-mimetic properties, offering therapeutic avenues.
- Understanding these complex biochemical interactions is crucial for unlocking the full therapeutic potential of inhaled NO therapy.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:20Inhalational Anesthetics: Overview
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation